Autografting in chronic myelogenous leukemia: new questions.

Angelo Michele Carella(San Antonio College), RS Negrin(Stanford University), Francesco Frassoni(Ospedale Policlinico San Martino)

PubMed

March 1, 1995

Cited by 14

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

|New England Journal of Medicine|2013|1.6k

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2015|740

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

|The Lancet|2018|733

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

|The Journal of Experimental Medicine|1991|623

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

|Journal of Clinical Oncology|2007|320